Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Emerging directions in tauopathy research.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Effect of Sevelamer and B. longum on Insulin Sensitivity in Participants With Obesity: A Randomized Clinical Trial.

Obesity (Silver Spring, Md.)·2026
Same author

Factors influencing accelerated progression in behavioral variant frontotemporal dementia.

Journal of neurology·2026
Same author

Revisiting an immunoneuropsychiatry classic: Sydenham's chorea.

Expert review of clinical immunology·2026
Same author

Decentralizing dementia research to the US-Mexico border: the Rio Grande Valley AD-RCMAR as a model for translational equity.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Examining neuroimaging biomarkers, plasma biomarkers and cognitive functions in patients with recovered COVID-19 infection: a multicentre study using 7T MRI.

Brain communications·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

A Campbell Sullivan1, Gabrielle Zuniga2, Paulino Ramirez3

  • 1Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio, TX, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Este estudio piloto sugiere que 3TC es seguro para pacientes con enfermedad de Alzheimer, reduciendo potencialmente la neuroinflamación y las placas amiloides al dirigirse a la activación de retrotransposones.

Palabras clave:
Enfermedad de Alzheimer3TCRetrotransposonesNeuroinflamaciónPlacas amiloidesEnsayo clínico

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Área de la Ciencia:

  • Neurociencia
  • Genética
  • Farmacología

Sus antecedentes:

  • Los retrotransposones comprenden el 40% del genoma humano y normalmente están silenciados.
  • Los retrotransposones activados están implicados en enfermedades neurodegenerativas como la enfermedad de Alzheimer (EA), impulsando la neurotoxicidad.
  • El inhibidor análogo de nucleósido de la transcriptasa inversa 3TC muestra potencial para mitigar la patología tau al dirigirse a la activación de retrotransposones.

Objetivo del estudio:

  • Evaluar la seguridad y viabilidad de dirigirse a la activación de retrotransposones en personas con enfermedad de Alzheimer utilizando 3TC.
  • Evaluar la captación del objetivo de 3TC y los efectos preliminares sobre la función cognitiva y los biomarcadores de neurodegeneración y neuroinflamación.

Principales métodos:

  • Un ensayo de etiqueta abierta de fase 2a (NCT04552795) con 12 participantes con deterioro cognitivo leve debido a sospecha de EA.
  • Los participantes recibieron 3TC oral diario (300 mg) durante 24 semanas.
  • Se evaluó la seguridad, la captación del objetivo, la función cognitiva y los biomarcadores de fluidos (líquido cefalorraquídeo y plasma).

Principales resultados:

  • El tratamiento con 3TC fue bien tolerado sin problemas de seguridad significativos.
  • La función cognitiva se mantuvo estable durante el período de estudio.
  • Las reducciones significativas en los niveles de proteína ácida fibrilar glial (GFAP) en el líquido cefalorraquídeo (P=0.03) indicaron una disminución de la neuroinflamación.
  • Las proporciones elevadas de Aβ42/40 en plasma (P=0.009) sugirieron una reducción de la carga de placas amiloides.

Conclusiones:

  • Este estudio piloto apoya la seguridad y la eficacia potencial de 3TC para dirigirse a la activación de retrotransposones en la enfermedad de Alzheimer.
  • Las reducciones observadas en la neuroinflamación y la carga amiloide justifican una mayor investigación.
  • Se necesitan ensayos más grandes y controlados con placebo para confirmar estos hallazgos y establecer la relevancia clínica.